SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 87,900
+300 (0.34%)
Nov 13, 2026, 3:30 PM KST
SK Biopharmaceuticals Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, SK Biopharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₩131,231. The average 1-year stock price forecast is 49.30% higher than the current stock price, while the lowest is ₩66,000 (-24.91%) and the highest is ₩160,000 (+82.03%).
Price Target: ₩131,231 (+49.30%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for SK Biopharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 12 | 12 | 12 | 12 | 13 |
Financial Forecast
Revenue This Year
987.35B
from 706.74B
Increased by 39.70%
Revenue Next Year
1.16T
from 987.35B
Increased by 17.68%
EPS This Year
3.84K
from 3.41K
Increased by 12.55%
EPS Next Year
5.19K
from 3.84K
Increased by 35.29%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.